What is Follistatin?
Follistatin is a secreted glycoprotein studied in research for its function as a ligand trap — a binding protein that sequesters members of the transforming growth factor-β (TGF-β) superfamily, preventing them from engaging their cognate receptor complexes. It is catalogued under CAS number 117628-82-7. The molecular weight of Follistatin depends on the form: recombinant full-length variants fall in the range of approximately 37,000–40,000 Da, while synthetic truncated forms run approximately 3,780 Da. Purity is characterized at 98.8% for the material supplied in the AminoKinetics catalog. All material is stored at −20°C in lyophilized form and is intended solely for research purposes, not for human or animal use.
Follistatin was initially characterized in the research literature through its capacity to suppress follicle-stimulating hormone (FSH) secretion in pituitary research models — a function that gave the protein its name. Subsequent research expanded its characterized binding profile to include activin A, activin B, and the growth and differentiation factor GDF-8 (also referred to as myostatin), as well as a subset of bone morphogenetic proteins (BMPs). This broad ligand-sequestration profile across the TGF-β superfamily is the primary reason Follistatin occupies a central position in research on extracellular regulation of TGF-β signaling cascades.
What is the domain architecture of Follistatin?
Follistatin has a defined multi-domain structure that determines both its ligand binding capacity and its interactions with heparin sulfate proteoglycans at the cell surface. The canonical architecture consists of:
N-terminal domain (ND). The follistatin N-terminal domain (also referred to as the FSND) contributes to activin binding and is necessary for high-affinity complex formation. It contains a cysteine-rich region that participates in the ligand-contact interface.
Three follistatin domain repeats (FSD1, FSD2, FSD3). These cysteine-rich modules are the structural units that make contact with ligand surfaces. Each follistatin domain contains a conserved core folded around a set of disulfide-bonded cysteines. The domain arrangement wraps around the activin or GDF-8 dimer, creating a high-affinity, largely irreversible sequestration complex. Crystallographic research has characterized the molecular contacts between individual FSD repeats and their ligand interfaces.
C-terminal acidic tail (isoform-dependent). The C-terminal region of Follistatin varies across isoforms and is a primary structural determinant of biological behavior, discussed below.
The multi-domain architecture means that Follistatin makes simultaneous contacts with both protomers of the ligand homodimer (e.g., activin A dimer), occluding the receptor-binding site on the ligand and preventing Type II receptor engagement.
What are the primary Follistatin isoforms and how do they differ?
Three major isoforms of Follistatin are referenced in the research literature, distinguished primarily by the length of the C-terminal acidic tail:
Follistatin-288 (FS288). The 288-amino acid isoform lacks the C-terminal acidic tail present in longer forms. FS288 has high affinity for cell-surface heparin sulfate proteoglycans due to the absence of the acidic tail's charge-neutralizing effect. This interaction restricts FS288 to cell surface-proximate signaling environments in research models, making it predominantly a local-acting form.
Follistatin-315 (FS315). This isoform is characterized as the predominant circulating form of endogenous Follistatin. The acidic C-terminal tail in FS315 reduces heparin sulfate binding affinity compared to FS288, allowing it to remain soluble and act at a distance from the site of secretion in research models.
Follistatin-344 (FS344). FS344 carries the longest isoform sequence including the full C-terminal tail and is the primary transcript isoform encoded from the FSTL (Follistatin-like) genetic locus. It is frequently the isoform used when the research context involves characterizing Follistatin's systemic ligand-sequestration function.
The distinction between isoforms is not academic from a research design standpoint. Selecting FS288 versus FS315/FS344 for an in vitro assay will produce different effective concentration-response behavior due to the heparin-binding difference. Researchers designing assays with Follistatin should specify which isoform they are working with, as the literature is not always explicit about this and results may vary accordingly.
What ligands does Follistatin sequester?
Follistatin binds a defined set of TGF-β superfamily ligands through the mechanism described above. The primary ligands characterized in the published research literature include:
Activin A and Activin B. Activins are homo- or heterodimers assembled from the βA and βB subunits (inhibin beta-A and inhibin beta-B). Activin A (βA/βA) and Activin B (βB/βB) are the most extensively characterized. Follistatin binds both with high affinity, forming a stable complex that prevents activin from engaging its receptor complex (ActRIIB or ActRIIA in combination with the Type I receptors ALK4 or ALK7).
GDF-8 (Myostatin). Growth and differentiation factor 8 — commonly referred to in the literature as myostatin — is a member of the TGF-β superfamily that is a characterized Follistatin ligand. Research on Follistatin's interaction with GDF-8 investigates the signaling consequences of GDF-8 sequestration at the level of receptor availability and downstream SMAD pathway activation. AminoKinetics makes no outcome claims regarding this interaction; it is studied at the receptor and signaling pathway level in research models.
Select BMP family members. Follistatin also binds BMP-2, BMP-4, and BMP-7, though with generally lower affinity than for activin A. BMP ligands signal through a partially overlapping but distinct receptor and SMAD pathway (SMAD1/5/9 rather than SMAD2/3), and Follistatin's capacity to modulate BMP signaling is a secondary research question relative to its activin-sequestration role.
What signaling pathways are affected by Follistatin in research models?
The signaling consequence of Follistatin-mediated ligand sequestration is defined by the pathways that each sequestered ligand would otherwise activate. The primary affected cascade is the canonical activin/TGF-β SMAD2/3 pathway:
Canonical SMAD2/3 signaling. Unsequestered activin or GDF-8 binds Type II receptors (ActRIIB or ActRIIA), which recruit and transphosphorylate Type I receptors (primarily ALK4 in the case of activin; ALK4 or ALK5 in other TGF-β family members). The activated Type I receptor then phosphorylates the receptor-regulated SMADs — specifically SMAD2 and SMAD3. Phosphorylated SMAD2/3 forms a heterocomplex with the co-SMAD SMAD4, and this complex translocates to the nucleus where it regulates transcription of SMAD-responsive target genes.
Follistatin's sequestration of activin or GDF-8 upstream of receptor engagement prevents this cascade from initiating at the ligand-receptor binding step. Research studies characterizing Follistatin's effect on SMAD signaling measure phospho-SMAD2 and phospho-SMAD3 levels as direct readouts of pathway activity in the presence and absence of Follistatin across concentration-response series.
BMP/SMAD1/5/9 signaling. When Follistatin sequesters BMP ligands, it inhibits signaling through the parallel SMAD1/5/9 branch. BMPs signal through Type II receptors (BMPR2, ActRIIA, ActRIIB) in combination with Type I receptors (ALK2, ALK3, ALK6), which phosphorylate SMAD1, SMAD5, and SMAD9. The degree to which Follistatin attenuates BMP signaling in a given research model depends on the relative affinity of the specific BMP for Follistatin versus its receptor, and on the concentration-response relationship between Follistatin and BMP in the experimental system.
What is the difference between recombinant and synthetic truncated Follistatin?
AminoKinetics supplies Follistatin in a form appropriate for research applications. Understanding the distinction between recombinant and synthetic truncated Follistatin is relevant for selecting the appropriate material:
Recombinant Follistatin (~37,000–40,000 Da). Produced in cell expression systems (typically CHO, E. coli, or insect cell expression), recombinant Follistatin is the full-length protein including post-translational modifications where the expression system permits. N-linked glycosylation sites in the native sequence influence circulating half-life and interact with serum proteins; recombinant material from mammalian expression systems will carry glycan structures absent in bacterially expressed material. Recombinant forms are used in research where the full-length protein context matters.
Synthetic truncated form (~3,780 Da). Synthetic truncated Follistatin corresponds to a peptide fragment derived from the Follistatin sequence rather than the full-length protein. Synthetic forms are accessible through solid-phase peptide synthesis and are used in research contexts studying specific domain fragments or peptide-level interactions. The substantially lower molecular weight (3,780 Da versus 37,000+ Da) reflects that this is a peptide fragment, not the full glycoprotein.
Researchers should specify which form is required for their experimental application, as the two are not interchangeable for most assay contexts.
What handling conditions apply to Follistatin in research?
Follistatin is supplied as a lyophilized powder and is stored at −20°C to preserve structural integrity. As a protein with multiple disulfide bonds across its follistatin domain repeats, it is sensitive to reducing agents, oxidation, elevated temperature, and repeated freeze-thaw cycles. Research handling practices that support reproducibility include cold storage, limiting thermal excursion, and avoiding reducing buffer conditions that can disrupt the disulfide-bonded architecture of the follistatin domains.
Cold-chain shipping is relevant for the same reasons. The folded structure of Follistatin is the basis for its ligand-binding function; partial denaturation or disulfide scrambling through temperature exposure will alter concentration-response behavior in binding assays without necessarily changing apparent purity in a post-shipping HPLC analysis. AminoKinetics ships all compounds cold-chain packaged as standard.
This article does not provide preparation instructions; handling protocols are determined by the researcher according to experimental requirements and applicable regulations.
How does AminoKinetics supply Follistatin?
AminoKinetics supplies Follistatin as a research-grade compound held to a purity specification of 98.8%, with mass spectrometry identity confirmation and batch-specific Certificate of Analysis included with every order as standard. All shipments are cold-chain packaged. Researchers can review specifications, available sizes, and pricing on the Follistatin compound page, or browse the full research catalog at all compounds.
For related research context, see our overviews of other TGF-β superfamily signaling compounds in the catalog. For background on how to interpret the analytical documentation included with each order, see analytical standards for research peptide sourcing. All material is intended for laboratory research use only, not for human or animal use.
This compound is a research chemical intended for laboratory and scientific research purposes only. It is not a drug, supplement, or food, and is not intended to diagnose, treat, cure, or prevent any disease. AminoKinetics does not sell products intended for human or animal use. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.